DRugwatch BlogRSS 2.0

DRugwatch Blog > January 2012 > Paula Deen and Questioning Celebrity Drug Endorsements

Paula Deen and Questioning Celebrity Drug Endorsements

Contributor: Allison Thrower

The pharmaceutical and entertainment industries have been abuzz since word dropped this week of Paula Deen’s type 2 diabetes diagnosis. The announcement offered an unexpected twist: the queen of Southern cuisine has also signed an endorsement deal with Novo Nordisk for its diabetes medication Victoza. The campaign called “Diabetes in a New Light” is meant to support healthy lifestyle changes in conjunction with the therapy – a stark contrast to Deen’s traditional tableau that consists of fried burgers on a glazed doughnut bun. A bold move by Novo, no doubt, but it’s certainly not the first of its kind.

Controversy aside, celebrities have been in the biopharma and healthcare spotlight for years – Bob Dole for Viagra, Sally Field for Boniva, Rob Lowe for Neulasta and now Paula Deen for Victoza. What other celebrities have successfully held sponsorships in the drug arena?

If time and tradition are any indicators, this will be an advertising trend for years to come. But still stands the question: just how efficacious or appropriate is this approach to drug promotion? And now that Deen’s endorsement has garnered public interest beyond the industry, how will celebrity pharmaceutical tie-ins be viewed or utilized in the future?
Posted on: 1/19/2012 6:15:13 PM | with 1 comments


Tags: Allison Thower, Just for Fun

Trackback URL: http://decisionresources.com/trackback/3c4d0c28-ea82-4ab5-9bcd-e6e733987aae/Paula-Deen-and-Questioning-Celebrity-Drug-Endorsements.aspx?culture=en-us

Comments
Donny Wong
So it didn't take long at all for the backlash to happen. A search on Twitter for "Deen" shows that Paula Deen, the unabashed queen of butter, has become the butt of countless jokes. And by association, Novo Nordisk is catching heat for selecting her as a spokesperson for Victoza.

Central to all the criticisms that have been circulating about the choice of Paula Deen is the disclosure that she has been diagnosed with type 2 diabetes for over three years, while continuing to showcase her Southern cooking style and encouraging millions of Americans to engage in an unhealthy, damaging lifestyle...and all while she sold cookbooks and collected endorsement fees.

And now that the diabetes cat is out of the bag, she insists that she will not change her eating habits (although now she is at least incorporating walking into her routine). What a wasted opportunity to use her diagnosis as a teaching tool.

Marketers often say that even negative publicity is good publicity. And life has certainly thrown Deen some lemons with the diabetes diagnosis, which she has turned into lemonade (to wash down some of those greasy fried foods). But it is difficult to see how Novo Nordisk will benefit from the association with Paula Deen, or indeed even keep their hands clean after coming into contact with all that sticky sugar and fat.
1/23/2012 11:29:13 AM

Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Next Steps for Vorapaxar: EU PAD Label and Antidote Development?
Post date:
2/17/2015 10:49:37 AM
Post Summary:

Stefanie Matlok Graeme GreeneWriiten by: Stefanie Hoffart and Graeme Green

Topic: Cardiovascular

On January 19, 2015, the European Medicines Agency (EMA) approved the thrombin receptor antagonist vorapaxar (Merck’s Zontivity) for secondary prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI), co-administered with acetylsalicylic acid (ASA) and, if necessary, clopidogrel.


Post title:
Bococizumab: Late to Great? Dyslipidemia Déjà vu?
Post date:
2/12/2015 3:58:28 PM
Post Summary:
Tim BlackstockContributor: Tim Blackstock
Topics: Cardiovascular

The link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well established, as is, the evidence showing that agents that reduce LDL-C can prevent CV events.

Post title:
Sandoz’s Biosimilar Filgrastim Scores Positive Recommendation from FDA Advisory Committee
Post date:
1/22/2015 3:44:26 PM
Post Summary:
Contributors: Anees Malik and Hristina Ivanova

The unanimous recommendation by the Oncologic Drugs Advisory Committee (ODAC) for FDA approval of Sandoz’s biosimilar filgrastim (EP2006; Zarxio)–the first biosimilar filing to be accepted in the United States– moves the biosimilar product tantalizingly close to FDA approval. Oncology, Biosimilars, “Anees Malik”, “Hristina Ivanova”

Post title:
AstraZeneca’s Brilinta Meets Primary End Point in PEGASUS-TIM 54 Study
Post date:
1/15/2015 4:53:03 PM
Post Summary:
Conor WalshContributor: Conor Walsh

AstraZeneca yesterday (January 14, 2015) announced that the Phase III PEGASUS-TIMI 54 study—a large-scale outcomes trial involving over 21,000 post-myocardial infarction (MI) patients—successfully met its primary efficacy end point. The company also reported that preliminary analysis did not reveal any unexpected safety issues. This study represents the first of several large studies that are set to complete over the next two years seeking to expand Brilinta’s (ticagrelor) label and drive sales growth.

Post title:
Cancer Drugs Funding in England is Flawed and Needs Reform
Post date:
1/14/2015 4:47:28 PM
Post Summary:

Contributor: Dan Roberts PhD

In 2011, the UK government introduced the Cancer Drugs Fund (CDF) in England, which funds cancer drugs which have not been deemed cost-effective or have not yet been assessed by the National Institute of Health and Care Excellence (NICE).

Decision Resources Group brands include: